The clinical study by Schmitt et al. demonstrated that co-administration of simvastatin, a CYP3A4 substrate, with a single IV dose of tocilizumab led to a 57% decrease in simvastatin exposure in RA patients [12]. This evidence concerns the gene CYP3A4 and rheumatoid arthritis.